committees information for the preceding year 
regarding the number and type of—
‘‘(i) arrests for drug violations; 
‘‘(ii) prosecutions for drug violations 
by United States Attorneys; and 
‘‘(iii) seizures of drugs by each com-
ponent of the Department of Justice seiz-
ing drugs, as well as statistical information 
on the geographic areas of such seizures. 
‘‘(C) SECRETARY
OF
HOMELAND
SECU-
RITY.—The Secretary of Homeland Security 
shall, by July 1 of each year, submit to the Di-
rector, the appropriate congressional commit-
tees, and the Committee on Homeland Security 
of the House of Representatives, and the Com-
mittee on Homeland Security and Govern-
mental Affairs of the Senate, information for 
the preceding year regarding—
‘‘(i) the number and type of seizures 
of drugs by each component of the Depart-
ment of Homeland Security seizing drugs, 
as well as statistical information on the ge-
ographic areas of such seizures; and 
‘‘(ii) the number of air and maritime 
patrol hours undertaken by each compo-
nent of that Department primarily dedi-
cated to drug supply reduction missions. 
‘‘(D) SECRETARY OF DEFENSE.—The Sec-
retary of Defense shall, by July 1 of each year, 
submit to the Director, the appropriate congres-
sional committees, the Committee on Armed 
Services of the House of Representatives, and 
the Committee on Armed Services of the Sen-
ate, information for the preceding year regard-
ing the number of air and maritime patrol 
hours primarily dedicated to drug supply reduc-
tion missions undertaken by each component of 
the Department of Defense.’’; 
(4) in subsection (b)(2)(B), by striking ‘‘Pro-
gram.’’ and inserting ‘‘Strategy.’’; and 
(5) in subsection (c), by striking ‘‘in’’ and in-
serting ‘‘on’’. 
SEC. 7. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, 
AND ASSESSMENT OF NATIONAL DRUG CON-
TROL STRATEGY. 
Section 706 (21 U.S.C. 1705) is amended to read as 
follows:
‘‘SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, 
AND ASSESSMENT OF NATIONAL DRUG CON-
TROL STRATEGY. 
‘‘(a) TIMING, CONTENTS, AND PROCESS FOR DEVEL-
OPMENT AND SUBMISSION OF NATIONAL DRUG CONTROL 
STRATEGY.—
‘‘(1) IN GENERAL.—Not later than February 1 
of each year, the President shall submit to Congress 
a National Drug Control Strategy, which shall set 
forth a comprehensive plan for reducing illicit drug 
use and the consequences of illicit drug use in the 
United States by reducing the demand for illegal 
drugs, limiting the availability of illegal drugs, and 
conducting law enforcement activities with respect to 
illegal drugs. 
‘‘(2) CONTENTS.—
‘‘(A) IN
GENERAL.—The National Drug 
Control Strategy submitted under paragraph 
(1) shall include the following: 
‘‘(i) Comprehensive, research-based, 
long-range, and quantifiable goals for re-
ducing illicit drug use and the con-
sequences of illicit drug use in the United 
States. 
‘‘(ii) Annual quantifiable objectives for 
demand reduction, supply reduction, and
law enforcement activities, specific targets 
to accomplish long-range quantifiable re-
duction in illicit drug use as determined by 
the Director, and specific measurements to 
evaluate progress toward the targets and 
strategic goals. 
‘‘(iii) A strategy to reduce the avail-
ability and purity of illegal drugs and the 
level of drug-related crime in the United 
States. 
‘‘(iv) An assessment of Federal effec-
tiveness in achieving the National Drug 
Control Strategy for the previous year, in-
cluding a specific evaluation of whether the 
objectives and targets for reducing illicit 
drug use for the previous year were met 
and reasons for the success or failure of 
the previous year’s Strategy. 
‘‘(v) Notification of any program or 
budget priorities that the Director expects 
to significantly change from the current 
Strategy over the next five years. 
‘‘(vi) A review of international, State, 
and local drug control activities to ensure 
that the United States pursues well-coordi-
nated and effective drug control at all lev-
els of government. 
‘‘(vii) A review of demand reduction 
activities by private sector entities and 
community-based organizations, including 
faith-based organizations, to determine 
their effectiveness and the extent of co-
operation, coordination, and mutual sup-
port between such entities and organiza-
tions and Federal, State, and local govern-
ment agencies. 
‘‘(viii) An assessment of current illicit 
drug use (including inhalants and steroids) 
and availability, impact of illicit drug use, 
and treatment availability, which assess-
ment shall include—
‘‘(I) estimates of drug prevalence 
and frequency of use as measured by 
national, State, and local surveys of il-
licit drug use and by other special 
studies of nondependent and depend-
ent illicit drug use; 
‘‘(II) illicit drug use in the work-
place and the productivity lost by such 
use; and
‘‘(III) 
illicit 
drug 
use 
by 
arrestees, probationers, and parolees. 
‘‘(ix) An assessment of the reduction 
of illicit drug availability, as measured 
by—
‘‘(I) the quantities of cocaine, 
heroin, marijuana, methamphetamine, 
ecstasy, and other drugs available for 
consumption in the United States; 
‘‘(II) the amount of marijuana, 
cocaine, heroin, methamphetamine, ec-
stasy, and precursor chemicals and 
other drugs entering the United 
States; 
‘‘(III) the number of illicit drug 
manufacturing laboratories seized and 
destroyed and the number of hectares 
of marijuana, poppy, and coca cul-
tivated and destroyed domestically 
and in other countries; 
‘‘(IV) the number of metric tons 
of marijuana, heroin, cocaine, and 
methamphetamine seized and other 
drugs; and
‘‘(V) changes in the price and 
purity of heroin, methamphetamine, 
and cocaine, changes in the price of 
ecstasy, 
and 
changes 
in 
tetrahydrocannabinol level of mari-
juana and other drugs. 
‘‘(x) An assessment of the reduction 
of the consequences of illicit drug use and 
availability, which shall include—
‘‘(I) the burden illicit drug users 
place on hospital emergency depart-
ments in the United States, such as 
the quantity of illicit drug-related 
services provided; 
‘‘(II) the annual national health 
care cost of illicit drug use; and 
‘‘(III) the extent of illicit drug-
related crime and criminal activity. 
‘‘(xi) A determination of the status of 
drug treatment in the United States, by 
assessing—
‘‘(I) public and private treatment 
utilization; and
‘‘(II) the number of illicit drug 
users the Director estimates meet di-
agnostic criteria for treatment. 
‘‘(xii) A review of the research agenda 
of the Counterdrug Technology Assessment 
Center to reduce the availability and abuse 
of drugs. 
‘‘(xiii) A summary of the efforts made 
to coordinate with private sector entities to 
conduct private research and development 
of medications to treat addiction by—
‘‘(I) screening chemicals for po-
tential therapeutic value; 
‘‘(II) developing promising com-
pounds; 
‘‘(III) conducting clinical trials; 
‘‘(IV) seeking Food and Drug 
Administration approval for drugs to 
treat addiction; 
‘‘(V) marketing the drug for the 
treatment of addiction; 
‘‘(VI) urging physicians to use 
the drug in the treatment of addic-
tion; and
‘‘(VII) 
encouraging 
insurance 
companies to reimburse the cost of 
the drug for the treatment of addic-
tion. 
‘‘(xiv) Such additional statistical data 
and information as the Director considers 
appropriate to demonstrate and assess 
trends relating to illicit drug use, the ef-
fects and consequences of illicit drug use, 
supply reduction, demand reduction, drug-
related law enforcement, and the imple-
mentation of the National Drug Control 
Strategy. 
‘‘(xv) A supplement reviewing the ac-
tivities of each individual National Drug 
Control Program agency during the pre-
vious year with respect to the National 
Drug Control Strategy and the Director’s 
assessment of the progress of each Na-
tional Drug Control Program agency in 
meeting its responsibilities under the Na-
tional Drug Control Strategy. 
‘‘(B) 
CLASSIFIED
INFORMATION.—Any 
contents of the National Drug Control Strategy 
that involve information properly classified
under criteria established by an Executive order 
shall be presented to Congress separately from 
the rest of the National Drug Control Strategy. 
‘‘(C) SELECTION OF DATA AND INFORMA-
TION.—In selecting data and information for 
inclusion under subparagraph (A), the Director 
shall ensure—
‘‘(i) the inclusion of data and informa-
tion that will permit analysis of current 
trends against previously compiled data 
and information where the Director be-
lieves such analysis enhances long-term as-
sessment of the National Drug Control 
Strategy; and 
‘‘(ii) the inclusion of data and infor-
mation to permit a standardized and uni-
form assessment of the effectiveness of 
drug treatment programs in the United 
States. 
‘‘(3) PROCESS FOR DEVELOPMENT AND SUB-
MISSION.—
‘‘(A) CONSULTATION.—In developing and 
effectively implementing the National Drug 
Control Strategy, the Director—
‘‘(i) shall consult with—
‘‘(I) the heads of the National 
Drug Control Program agencies; 
‘‘(II) Congress; 
‘‘(III) State and local officials; 
‘‘(IV) private citizens and organi-
zations, including community- and 
faith-based organizations, with experi-
ence and expertise in demand reduc-
tion; 
‘‘(V) private citizens and organi-
zations with experience and expertise 
in supply reduction; 
‘‘(VI) private citizens and organi-
zations with experience and expertise 
in law enforcement; and 
‘‘(VII) appropriate representa-
tives of foreign governments; 
‘‘(ii) with the concurrence of the At-
torney General, may require the El Paso 
Intelligence Center to undertake specific 
tasks or projects to implement the Na-
tional Drug Control Strategy; 
‘‘(iii) with the concurrence of the Di-
rector of National Intelligence and the At-
torney General, may request that the Na-
tional Drug Intelligence Center undertake 
specific tasks or projects to implement the 
National Drug Control Strategy; and 
‘‘(iv) may make recommendations to 
the Secretary of Health and Human Serv-
ices on research that supports or advances 
the National Drug Control Strategy. 
‘‘(B) COMMITMENT
TO
SUPPORT
STRAT-
EGY.—In satisfying the requirements of sub-
paragraph (A)(i), the Director shall ensure, to 
the maximum extent possible, that State and 
local officials and relevant private organizations 
commit to support and take steps to achieve the 
goals and objectives of the National Drug Con-
trol Strategy. 
‘‘(C) RECOMMENDATIONS.—Recommenda-
tions under subparagraph (A)(iv) may include 
recommendations of research to be performed 
at the National Institutes of Health, including 
the National Institute on Drug Abuse, or any 
other appropriate agency within the Depart-
ment of Health and Human Services. 
‘‘(D) INCLUSION IN STRATEGY.—The Na-
tional Drug Control Strategy under this sub-
section shall include a list of each entity con-
sulted under subparagraph (A)(i). 
‘‘(4) SUBMISSION OF REVISED STRATEGY.—The 
President may submit to Congress a revised Na-
tional Drug Control Strategy that meets the require-
ments of this section—
‘‘(A) at any time, upon a determination by 
the President, in consultation with the Director, 
that the National Drug Control Strategy in ef-
fect is not sufficiently effective; or 
‘‘(B) if a new President or Director takes 
office. 
‘‘(b) PERFORMANCE MEASUREMENT SYSTEM.—Not 
later than February 1 of each year, the Director shall sub-
mit to Congress, as part of the National Drug Control 
Strategy, a description of a national drug control perform-
ance measurement system that—
‘‘(1) develops 2-year and 5-year performance 
measures and targets for each National Drug Con-
trol Strategy goal and objective established for re-
ducing drug use, drug availability, and the con-
sequences of drug use; 
‘‘(2) describes the sources of information and 
data that will be used for each performance measure
incorporated into the performance measurement sys-
tem; 
‘‘(3) identifies major programs and activities of 
the National Drug Control Program agencies that 
support the goals and annual objectives of the Na-
tional Drug Control Strategy; 
‘‘(4) evaluates the contribution of demand re-
duction and supply reduction activities implemented 
by each National Drug Control Program agency in 
support of the National Drug Control Strategy; 
‘‘(5) monitors consistency of drug-related goals 
and objectives among the National Drug Control 
Program agencies and ensures that each agency’s 
goals, objectives, and budgets support and are fully 
consistent with the National Drug Control Strategy; 
and 
‘‘(6) coordinates the development and imple-
mentation of national drug control data collection 
and reporting systems to support policy formulation 
and performance measurement, including an assess-
ment of—
‘‘(A) the quality of current drug use meas-
urement instruments and techniques to measure 
supply reduction and demand reduction activi-
ties;
‘‘(B) the adequacy of the coverage of exist-
ing national drug use measurement instruments 
and techniques to measure the illicit drug user 
population, and groups that are at risk for il-
licit drug use; and 
‘‘(C) the adequacy of the coverage of exist-
ing national treatment outcome monitoring sys-
tems to measure the effectiveness of drug abuse 
treatment in reducing illicit drug use and crimi-
nal behavior during and after the completion of 
substance abuse treatment; and 
‘‘(7) identifies the actions the Director shall 
take to correct any inadequacies, deficiencies, or lim-
itations identified in the assessment described in 
paragraph (6). 
‘‘(c) MODIFICATIONS.—A description of any modi-
fications made during the preceding year to the national 
drug performance measurement system described in sub-
section (b) shall be included in each report submitted 
under subsection (a).’’. 
SEC. 8. HIGH INTENSITY DRUG TRAFFICKING AREAS PRO-
GRAM. 
Section 707 (21 U.S.C. 1706) is amended to read as 
follows:
‘‘SEC. 707. HIGH INTENSITY DRUG TRAFFICKING AREAS 
PROGRAM. 
‘‘(a) ESTABLISHMENT.—
‘‘(1) IN GENERAL.—There is established in the 
Office a program to be known as the High Intensity 
Drug Trafficking Areas Program (in this section re-
ferred to as the ‘Program’). 
‘‘(2) PURPOSE.—The purpose of the Program 
is to reduce drug trafficking and drug production in 
the United States by—
‘‘(A) facilitating cooperation among Fed-
eral, State, and local law enforcement agencies 
to share information and implement coordinated 
enforcement activities; 
‘‘(B) enhancing intelligence sharing among 
Federal, State, and local law enforcement agen-
cies; 
‘‘(C) providing reliable intelligence to law 
enforcement agencies needed to design effective 
enforcement strategies and operations; and 
‘‘(D) supporting coordinated law enforce-
ment strategies which maximize use of available 
resources to reduce the supply of illegal drugs 
in designated areas and in the United States as 
a whole.
‘‘(b) DESIGNATION.—The Director, upon consulta-
tion with the Attorney General, the Secretary of the 
Treasury, the Secretary of Homeland Security, heads of 
the National Drug Control Program agencies, and the 
Governor of each applicable State, may designate any 
specified area of the United States as a high intensity 
drug trafficking area. After making such a designation 
and in order to provide Federal assistance to the area so 
designated, the Director may—
‘‘(1) obligate such sums as are appropriated for 
the Program; 
‘‘(2) direct the temporary reassignment of Fed-
eral personnel to such area, subject to the approval 
of the head of the department or agency that em-
ploys such personnel; 
‘‘(3) take any other action authorized under 
section 704 to provide increased Federal assistance 
to those areas; and 
‘‘(4) coordinate activities under this section 
(specifically administrative, recordkeeping, and funds 
management activities) with State and local officials. 
‘‘(c) PETITIONS FOR DESIGNATION.—The Director 
shall establish regulations under which a coalition of inter-
ested law enforcement agencies from an area may petition 
for designation as a high intensity drug trafficking area.